Published in Oncologist on February 09, 2010
Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm? Curr Oncol (2015) 1.14
Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer. Sci Rep (2015) 1.10
Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer. Radiat Oncol J (2013) 0.79
Response to radiation in renal medullary carcinoma. Rare Tumors (2011) 0.77
Research progress in the treatment of small cell lung cancer. J Cancer (2017) 0.75
Resected small cell lung cancer-time for more? J Thorac Dis (2016) 0.75
Systemic Chemotherapy for Progression of Brain Metastases in Extensive-Stage Small Cell Lung Cancer. Case Rep Oncol Med (2015) 0.75
Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer. Drug Des Devel Ther (2013) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol (2006) 7.87
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med (2002) 7.59
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med (1999) 5.84
A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med (1992) 5.10
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol (2006) 3.71
Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol (1997) 3.45
Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol (1992) 3.27
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst (1995) 3.25
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol (2002) 2.89
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol (2009) 2.73
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2009) 2.58
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol (2009) 2.53
Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 (1973) 2.44
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1993) 2.22
Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med (1987) 2.05
Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol (2005) 2.04
Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol (2005) 1.96
Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol (2003) 1.94
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys (2004) 1.83
Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.81
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol (2006) 1.69
Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.62
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol (1990) 1.57
Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer (2002) 1.53
Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol (2006) 1.39
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol (2004) 1.37
Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol (1997) 1.32
Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer (2009) 1.22
Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol (1998) 1.21
Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol (2004) 1.21
Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer. J Clin Oncol (1986) 1.19
Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev (2005) 1.17
Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging (2004) 1.13
Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev (2007) 1.12
Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol (2000) 1.11
Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys (2005) 1.09
Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Ann Oncol (2002) 1.05
Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol (2007) 1.01
Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer (2005) 1.01
Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol (1998) 1.01
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol (2007) 1.00
Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol (1993) 1.00
Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol (1998) 0.96
Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer (2006) 0.95
A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am J Clin Oncol (2005) 0.95
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol (2009) 0.92
Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys (1995) 0.92
Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res (2005) 0.92
Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Lung Cancer (1998) 0.91
Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep (1983) 0.89
Central nervous system metastases in small cell bronchogenic carcinoma. Semin Oncol (1978) 0.88
Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions. Clin Lung Cancer (2005) 0.84
A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. J Thorac Oncol (2009) 0.81
Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol (2001) 0.80
Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study. Lung Cancer (2002) 0.78
Increased frequency of the S allele of the L-myc oncogene in non-Hodgkin's lymphoma. Br J Cancer (1994) 0.78
A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer. Jpn J Clin Oncol (2000) 0.77
Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12. J Clin Oncol (2000) 0.76
A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs (2006) 0.76
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2010) 2.69
Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys (2013) 1.24
Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys (2004) 0.97
Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys (2005) 0.86
ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases. J Palliat Med (2014) 0.81
ACR Appropriateness Criteria® follow-up and retreatment of brain metastases. Am J Clin Oncol (2012) 0.80
Muscle endurance, cancer-related fatigue, and radiotherapy in prostate cancer survivors. Muscle Nerve (2011) 0.77
Brain metastases in very young patients with lung cancer are still brain metastases. Onkologie (2008) 0.77